FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023621352> ?p ?o ?g. }

• W2023621352 endingPage "51" @default.
• W2023621352 startingPage "45" @default.
• W2023621352 abstract "<h3>Objective</h3> To prospectively analyse the risk for disease relapses in patients with rheumatoid arthritis (RA) in sustained remission, either continuing, tapering or stopping disease-modifying antirheumatic drugs (DMARDs) in a prospective randomised controlled trial. <h3>Methods</h3> Reduction of Therapy in patients with Rheumatoid arthritis in Ongoing remission is a multicentre, randomised controlled, parallel-group phase 3 trial evaluating the effects of tapering and stopping all conventional and/or biological DMARDs in patients with RA in stable remission. Patients (disease activity score 28 (DAS28)<2.6 for least 6 months) were randomised into three arms, either continuing DMARDs (arm 1), tapering DMARDs by 50% (arm 2) or stopping DMARDs after 6 months tapering (arm 3). The primary endpoint was sustained remission during 12 months. <h3>Results</h3> In this interim analysis, the first 101 patients who completed the study were analysed. At baseline, all patients fulfilled DAS28 remission and 70% also American College of Rheumatology- European League Against Rheumatism Boolean remission. 82.2% of the patients received methotrexate, 40.6% biological DMARDs and 9.9% other DMARDs. Overall, 67 patients (66.3%) remained in remission for 12 months, whereas 34 patients (33.7%) relapsed. The incidence of relapses was related to study arms (p=0.007; arm 1: 15.8%; arm 2: 38.9%; arm 3: 51.9%). Multivariate logistic regression identified anticitrullinated protein antibodies (ACPA) positivity (p=0.038) and treatment reduction (in comparison to continuation) as predictors for relapse (arm 2: p=0.012; arm 3: p=0.003). <h3>Conclusions</h3> This randomised controlled study testing three different treatment strategies in patients with RA in sustained remission demonstrated that more than half of the patients maintain in remission after tapering or stopping conventional and biological DMARD treatment. Relapses occurred particularly in the first 6 months after treatment reduction and were associated with the presence of ACPA. <h3>Trial registration number</h3> 2009-015740-42." @default.
• W2023621352 created "2016-06-24" @default.
• W2023621352 creator A5000359142 @default.
• W2023621352 creator A5002520863 @default.
• W2023621352 creator A5004105963 @default.
• W2023621352 creator A5012973190 @default.
• W2023621352 creator A5013085430 @default.
• W2023621352 creator A5013492221 @default.
• W2023621352 creator A5016601495 @default.
• W2023621352 creator A5022588052 @default.
• W2023621352 creator A5030519148 @default.
• W2023621352 creator A5033544980 @default.
• W2023621352 creator A5033815543 @default.
• W2023621352 creator A5037760876 @default.
• W2023621352 creator A5042208174 @default.
• W2023621352 creator A5045378260 @default.
• W2023621352 creator A5045623356 @default.
• W2023621352 creator A5050747830 @default.
• W2023621352 creator A5053190244 @default.
• W2023621352 creator A5056323490 @default.
• W2023621352 creator A5059789259 @default.
• W2023621352 creator A5061010923 @default.
• W2023621352 creator A5066439668 @default.
• W2023621352 creator A5070887882 @default.
• W2023621352 creator A5075261558 @default.
• W2023621352 creator A5079285531 @default.
• W2023621352 date "2015-02-06" @default.
• W2023621352 modified "2023-10-11" @default.
• W2023621352 title "Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study" @default.
• W2023621352 cites W1580435844 @default.
• W2023621352 cites W1974718865 @default.
• W2023621352 cites W1985004174 @default.
• W2023621352 cites W2005429018 @default.
• W2023621352 cites W2021296708 @default.
• W2023621352 cites W2024988150 @default.
• W2023621352 cites W2025591723 @default.
• W2023621352 cites W2028646119 @default.
• W2023621352 cites W2044940757 @default.
• W2023621352 cites W2062696198 @default.
• W2023621352 cites W2063811338 @default.
• W2023621352 cites W2075327204 @default.
• W2023621352 cites W2104669609 @default.
• W2023621352 cites W2107756455 @default.
• W2023621352 cites W2110177517 @default.
• W2023621352 cites W2110826367 @default.
• W2023621352 cites W2112953069 @default.
• W2023621352 cites W2113476392 @default.
• W2023621352 cites W2137251251 @default.
• W2023621352 cites W2137825059 @default.
• W2023621352 cites W2142396487 @default.
• W2023621352 cites W2145786982 @default.
• W2023621352 cites W2152553239 @default.
• W2023621352 cites W2155109530 @default.
• W2023621352 cites W2160340969 @default.
• W2023621352 cites W2161249330 @default.
• W2023621352 cites W2161660543 @default.
• W2023621352 cites W2168751860 @default.
• W2023621352 cites W2323815252 @default.
• W2023621352 cites W4210768724 @default.
• W2023621352 cites W4295125684 @default.
• W2023621352 doi "https://doi.org/10.1136/annrheumdis-2014-206439" @default.
• W2023621352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25660991" @default.
• W2023621352 hasPublicationYear "2015" @default.
• W2023621352 type Work @default.
• W2023621352 sameAs 2023621352 @default.
• W2023621352 citedByCount "158" @default.
• W2023621352 countsByYear W20236213522014 @default.
• W2023621352 countsByYear W20236213522015 @default.
• W2023621352 countsByYear W20236213522016 @default.
• W2023621352 countsByYear W20236213522017 @default.
• W2023621352 countsByYear W20236213522018 @default.
• W2023621352 countsByYear W20236213522019 @default.
• W2023621352 countsByYear W20236213522020 @default.
• W2023621352 countsByYear W20236213522021 @default.
• W2023621352 countsByYear W20236213522022 @default.
• W2023621352 countsByYear W20236213522023 @default.
• W2023621352 crossrefType "journal-article" @default.
• W2023621352 hasAuthorship W2023621352A5000359142 @default.
• W2023621352 hasAuthorship W2023621352A5002520863 @default.
• W2023621352 hasAuthorship W2023621352A5004105963 @default.
• W2023621352 hasAuthorship W2023621352A5012973190 @default.
• W2023621352 hasAuthorship W2023621352A5013085430 @default.
• W2023621352 hasAuthorship W2023621352A5013492221 @default.
• W2023621352 hasAuthorship W2023621352A5016601495 @default.
• W2023621352 hasAuthorship W2023621352A5022588052 @default.
• W2023621352 hasAuthorship W2023621352A5030519148 @default.
• W2023621352 hasAuthorship W2023621352A5033544980 @default.
• W2023621352 hasAuthorship W2023621352A5033815543 @default.
• W2023621352 hasAuthorship W2023621352A5037760876 @default.
• W2023621352 hasAuthorship W2023621352A5042208174 @default.
• W2023621352 hasAuthorship W2023621352A5045378260 @default.
• W2023621352 hasAuthorship W2023621352A5045623356 @default.
• W2023621352 hasAuthorship W2023621352A5050747830 @default.
• W2023621352 hasAuthorship W2023621352A5053190244 @default.
• W2023621352 hasAuthorship W2023621352A5056323490 @default.
• W2023621352 hasAuthorship W2023621352A5059789259 @default.
• W2023621352 hasAuthorship W2023621352A5061010923 @default.
• W2023621352 hasAuthorship W2023621352A5066439668 @default.

• next